TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs.
TNF inhibitors help to block the TNF alpha that occurs naturally in
the body and causes inflammation. TNF drugs are used to reduce
inflammation and stop disease progression by targeting the tumor
necrosis factor, which is an inflammation-causing substance. TNF
inhibitor drugs are employed to treat inflammatory conditions such as
rheumatoid arthritis and juvenile arthritis. Generally, in the
healthy person, the TNF levels remain steady. However, in a patient
with rheumatoid arthritis, the level of TNF is increasing which leads
to more inflammation. TNF inhibitor drugs act as blockers for TNF
substances. TNF alpha blockers are highly effective in the treatment
of patients with active rheumatoid arthritis. These drugs are used in
patients as a conventional second-line treatments.
Report Overview @
https://www.transparencymarketresearch.com/tnf-inhibitors-market.html
Based on drug, the TNF inhibitors market can be segmented into
etanercept, infliximab, adalimumab, certolizumab, and golimumab. The
adalimumab segment is likely to expand at a significant pace during
the forecast period. The drug is effectively used in a broad range of
pain management therapies and is widely available over the counter.
Based on distribution channel, the TNF inhibitors market can be
segmented into hospital pharmacy and retail pharmacy. The hospital
pharmacy segment is likely to expand at a significant pace between
2017 and 2025, this is because patients with rheumatoid arthritis,
arthritis give more preference to the hospitals for treatment.
Increase in elderly population and rise in the prevalence of
rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel
disease are some of the factors that drive the TNF inhibitors market.
According to the National Health Interview Survey, in 2016, almost
20% of the global population was reported to be suffering from
chronic pain, with rheumatoid arthritis being one of the major
reasons. Moreover, according to the Center for Disease Control and
Prevention, by 2040, approximately 78 million (26%) of the U.S.
adults are projected to have arthritis. Owing to this, the
consumption of TNF inhibitor dugs is likely to increase rapidly in
the near future. However, side-effects associated with the use of TNF
inhibitor drugs such as skin irritation, flushing, headache, and
abdominal pain are estimated to hinder the market in the next few
years.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36113
In terms of region, the global TNF inhibitors market can be segmented
into North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. North America is the leading market share,
primarily due to favorable reimbursement policies for pain management
prescription drugs in the region. Lenient regulations in Europe are
playing a key role in the increased rate of development, approval,
and commercialization of innovative molecule combinations in the pain
management. This is likely to fuel the market in Europe during the
forecast period. The increasing prevalent population and launching of
new products are estimated to drive the market in Asia Pacific during
the forecast period. Despite sustained growth and development Middle
East & Africa had faced several health challenges over the last
decade. Factors such as economic resources, adequate health care
facilities, and growing burden of communicable diseases are likely to
propel the market in the region from 2017 to 2025. Moreover,
rheumatology services are limited or non-existent in several parts of
sub-Saharan Africa. Hence, making these services available may boost
the market in Middle East & Africa during the forecast period.
Major players operating in the global TNF inhibitors market are
Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mochida
Pharmaceutical, Hanall, BioPharma, GalxoSmithKline, and Janssen
Biotech.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=36113<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment